中国麻风皮肤病杂志 ›› 2022, Vol. 38 ›› Issue (11): 790-793.doi: 10.12144/zgmfskin202211790

• 论著 • 上一篇    下一篇

真实世界度普利尤单抗治疗儿童中重度特应性皮炎15例疗效观察

江斐1,2,赵晴2,孙勇虎2,张朝霞2,杨宝琦2,杨青2,刘国艳2,施仲香2,刘红2,张福仁1,2   

  1. 1山东大学，山东济南，250012；2山东第一医科大学附属皮肤病医院（山东省皮肤病医院），山东省皮肤病性病防治研究所，山东济南，250022
  • 出版日期:2022-11-15 发布日期:2022-10-25

Efficacy of dupilumab in 5 children with moderate-to-severe atopic dermatitis: a real-world study

JIANG Fei1,2, ZHAO Qing2, SUN Yonghu2, ZHANG Zhaoxia2, YANG Baoqi2, YANG Qing2, LIU Guoyan2, SHI Zhongxiang2, LIU Hong2, ZHANG Furen1,2   

  1. 1 Shandong University, Jinan 250012, China; 2 Shandong Provincial Hospital for Skin Diseases & Shandong Provincial Institute of Dermatology and Venereology, Shandong First Medical University & Shandong Academy of Medical Sciences, Jinan 250022, China
  • Online:2022-11-15 Published:2022-10-25

PDF (PC)

196

摘要： 目的：评估真实世界下度普利尤单抗治疗儿童中重度特应性皮炎的有效性和安全性。方法：收集2020年11月至2022年3月于我院使用度普利尤单抗治疗的15例1～12岁儿童中重度AD患者信息，比较药物治疗前、治疗4周、12周、16周的SCORAD、EASI、瘙痒NRS的评分变化，记录治疗过程中的不良反应。结果：本研究共纳入15例患者。研究结果表明，与基线相比,治疗后第4、12和16周时SCORAD评分分别下降了43.4%、63.3%、72.6%；EASI评分分别下降了52.8%、73.2%、86.7%；瘙痒NRS评分下降了52.8%、72.2%、83.8%。在第12周随访时，有50.0%的患者达到了EASI-75，10.0%的患者达到了EASI-90。在16周时，达到这两项指标的比例增加到75.0%和50.0%。随访期间所有患者均未出现不良反应及严重不良事件。结论：度普利尤单抗对儿童中重度特应性皮炎具有良好的疗效，且安全性较高。

关键词: 度普利尤单抗, 特应性皮炎, 儿童, 真实世界

Abstract: Objective: To evaluate the efficacy and safety of dupilumab in the treatment of moderate-to-severe atopic dermatitis (AD) in children in the real world. Methods: The data of pediatric patients with moderate-to-severe AD treated with dupilumab from November 2020 to March 2022 were collected, and changes in SCORAD, EASI, and pruritic NRS scores before and at weeks 4, 12, and 16 during treatment were compared, and adverse effects during treatment were recorded. Results: A total of 15 patients were enrolled in this study. The results showed that compared with baseline, SCORAD scores decreased by 43.4%, 63.3%, and 72.6%at weeks 4, 12, and 16 post-treatment, respectively. EASI scores decreased by 52.8%, 73.2%, 86.7%. Pruritus NRS scores decreased by 52.8%, 72.2%, 83.8%. At week 12 follow-up, 50.0% of patients had achieved EASI-75 and 10.0% had achieved EASI-90. At week 16, the percentage of patients achieving both metrics increased to 75.0% and 50.0%. No adverse reactions or serious adverse events were observed in all patients during the follow-up period. Conclusion: Dupilumab has good efficacy and a high safety profile in children with moderate-to-severe atopic dermatitis.

Key words: dupilumab, atopic dermatitis, children, real world